Stockreport

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice [Yahoo! Finance]

OptiNose, Inc.  (OPTN) 
Last optinose, inc. earnings: 3/5 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.optinose.com
PDF FDA Supplemental New Drug Application Filed with Prescription Drug User Fee Act Target Goal Date of March 16, 2024 YARDLEY, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Opt [Read more]